Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Diagnosis of functional HoFH by either genetic or clinical criteria as defined in the protocol~2. LDL-C \>130 mg/dL at the screening visit~3. Body weight ≥15 kg~4. Receiving stable maximally tolerated therapy\*at the screening visit \*Maximally tolerated therapy could include a daily statin.~5. Willing and able to comply with clinic visits and study-related procedures~6. Parent(s) or legal guardian(s) must provide the signed informed consent form (ICF). Patients ≥5 years of age (or above age determined by the IRB/EC and in accordance with the local regulations and requirements) must also provide informed assent forms (IAFs) to enroll in the study, and sign and date a separate IAF or ICF signed by the parent(s)/legal guardian(s) (as appropriate based on local regulations and requirements)~Key Exclusion Criteria:~1. Background pharmacologic LMT, nutraceuticals or over-the-counter (OTC) therapies known to affect lipids, at a dose/regimen that has not been stable for at least 4 weeks (8 weeks for PCSK9 inhibitors) before the screening visit and patient is unwilling to enter the run-in period~2. For patients entering Part A, unable to temporarily discontinue apheresis from the baseline visit through the week 4 visit~3. Receiving lipid apheresis, a setting (if applicable) and schedule that has not been stable for approximately 8 weeks before the screening visit or an apheresis schedule that is not anticipated to be stable over the duration of the treatment period (48 weeks).~4. Plasmapheresis within 8 weeks of the screening visit, or plans to undergo plasmapheresis during Part A or Part B~5. Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins~6. Newly diagnosed (within 3 months prior to randomization visit) diabetes mellitus or poorly controlled diabetes as defined in the protocol~Note: Other protocol-defined criteria apply

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Evinacumab (Type: EXPERIMENTAL): Part A: Single intravenous (IV) dose Part B: IV dose every 4 weeks (Q4W) until week 20 Part C: IV dose Q4W

Based on this trial design, predict the completion outcome and termination type (if applicable).